MedPath

Bausch Health Companies Inc

🇨🇦Canada
Ownership
-
Employees
20.2K
Market Cap
$2.1B
Website
Introduction

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

patientcareonline.com
·

Bausch Health Presents Phase 3 Study Design for Investigational ...

Bausch Health and Salix Pharmaceuticals presented the RED-C clinical trial program design at The Liver Meeting 2024, evaluating a next-gen SSD immediate-release rifaximin to delay first overt hepatic encephalopathy (OHE) hospitalization. The RED-C program includes two phase 3, randomized, double-blind, placebo-controlled trials in adults with cirrhosis and medically controlled ascites, with enrollment complete and topline data expected in H1 2026.
openpr.com
·

Atopic Dermatitis Market 2024: Key Trends, Innovations, and Growth Forecast

The atopic dermatitis market is projected to grow from $7.51 billion in 2023 to $15.27 billion by 2028, driven by advancements in biologic therapies, personalized medicine, and product innovations. Key players include Sanofi SA, Regeneron Pharmaceuticals Inc., and Novartis International AG.
globenewswire.com
·

Milestone Pharmaceuticals Reports Third Quarter 2024

Milestone Pharmaceuticals reported Q3 2024 financials, focusing on potential FDA approval for CARDAMYST nasal spray for PSVT, with a PDUFA date set for March 27, 2025. The company also plans to initiate a Phase 3 trial for etripamil in AFib-RVR in H1 2025. Financial highlights include a net loss of $9.4 million for Q3 2024, with cash, cash equivalents, and short-term investments totaling $76.4 million as of September 30, 2024.
equitypandit.com
·

Alembic Pharma Receives USFDA Approval for Hypertension Drug

Alembic Pharma received USFDA approval for Diltiazem Hydrochloride Extended-Release capsules, used for hypertension, available in dosages of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, with a market value of $105.3 million as of June 2024.
indiainfoline.com
·

Alembic Pharma gets USFDA approval hypertension drug

Alembic Pharmaceuticals received FDA approval for Diltiazem Hydrochloride Extended-Release capsules, offering a generic alternative to Bausch Health’s Cardizem CD in the US market, valued at $105.3 million by June 2024. The approval adds to Alembic’s 218 ANDA approvals from the USFDA, reinforcing its position in the generics industry.
cnbctv18.com
·

Alembic Pharma gets USFDA nod for hypertension treatment drug

Alembic Pharmaceuticals receives USFDA approval for Diltiazem Hydrochloride Extended-Release capsules, offering a generic alternative to Cardizem CD capsules. These capsules, available in various dosages, treat hypertension and angina, with an estimated market size of $105.3 million. Alembic now has 218 ANDA approvals from the USFDA.
globenewswire.com
·

Oral Proteins & Peptides Market Research: Semaglutide

The global oral proteins and peptides market is projected to reach USD 20.36 billion by 2029, driven by increasing demand for oral peptides in treating chronic diseases, R&D investments, and advancements in drug delivery technologies. The US dominates the market, supported by a strong biopharmaceutical sector and presence of key players like Novo Nordisk and Pfizer. Semaglutide leads in molecule segments, used for managing type-2 diabetes and obesity.
prnewswire.com
·

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising ...

Global gastroparesis drugs market to grow by USD 1.42 billion from 2024-2028, driven by rising diabetes prevalence and emerging market opportunities, despite stringent regulatory challenges. Key players include Abbott Laboratories, AbbVie Inc., and others.
clarivate.com
·

Hidradenitis Suppurativa - Current Treatment - Treatment Algorithms: Claims Data Analysis

HS is a chronic inflammatory disorder affecting hair follicles, characterized by painful, fluid-filled lesions. Humira was the sole FDA-approved therapy until Cosentyx's approval in Oct 2023. Off-label treatments like antibiotics precede biologics. This analysis covers HS treatment trends, Humira's integration, patient progression rates, and therapy combinations, using real-world claims data.

Oral Proteins and Peptides Market Analysis and Forecast 2024-2031

Chapters cover methodology, executive summary, market variables, segmentation by disease, molecule, biological target, mechanism, and region, and competitive landscape.
© Copyright 2025. All Rights Reserved by MedPath